JP2024543379A - サイロシビンによる治療抵抗性うつ病の治療 - Google Patents

サイロシビンによる治療抵抗性うつ病の治療 Download PDF

Info

Publication number
JP2024543379A
JP2024543379A JP2024527357A JP2024527357A JP2024543379A JP 2024543379 A JP2024543379 A JP 2024543379A JP 2024527357 A JP2024527357 A JP 2024527357A JP 2024527357 A JP2024527357 A JP 2024527357A JP 2024543379 A JP2024543379 A JP 2024543379A
Authority
JP
Japan
Prior art keywords
psilocybin
dose
subject
administration
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543379A5 (https=
Inventor
アンソニー ミル，トレバー
マニング グッドウィン，ギー
ツァイ，ジョイス
マーウッド，リンジー
ミストリー，スニール
Original Assignee
コンパス パスファインダー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンパス パスファインダー リミテッド filed Critical コンパス パスファインダー リミテッド
Publication of JP2024543379A publication Critical patent/JP2024543379A/ja
Publication of JP2024543379A5 publication Critical patent/JP2024543379A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024527357A 2021-11-09 2022-11-02 サイロシビンによる治療抵抗性うつ病の治療 Pending JP2024543379A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163277407P 2021-11-09 2021-11-09
US63/277,407 2021-11-09
US202163284973P 2021-12-01 2021-12-01
US63/284,973 2021-12-01
PCT/US2022/048713 WO2023086252A1 (en) 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin

Publications (2)

Publication Number Publication Date
JP2024543379A true JP2024543379A (ja) 2024-11-21
JP2024543379A5 JP2024543379A5 (https=) 2025-10-24

Family

ID=84799979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527357A Pending JP2024543379A (ja) 2021-11-09 2022-11-02 サイロシビンによる治療抵抗性うつ病の治療

Country Status (8)

Country Link
US (1) US20250000881A1 (https=)
EP (1) EP4429671A1 (https=)
JP (1) JP2024543379A (https=)
KR (1) KR20240110816A (https=)
AU (1) AU2022387053A1 (https=)
CA (1) CA3237885A1 (https=)
MX (1) MX2024005632A (https=)
WO (1) WO2023086252A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
TW202304466A (zh) * 2021-03-30 2023-02-01 英商康派斯開拓者公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
GB2588505B (en) * 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
TW202304466A (zh) * 2021-03-30 2023-02-01 英商康派斯開拓者公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法

Also Published As

Publication number Publication date
CA3237885A1 (en) 2023-05-19
EP4429671A1 (en) 2024-09-18
WO2023086252A1 (en) 2023-05-19
MX2024005632A (es) 2024-07-29
US20250000881A1 (en) 2025-01-02
KR20240110816A (ko) 2024-07-16
AU2022387053A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JP2025039633A (ja) サイロシビンによるうつ病及び他の様々な障害の治療
JP2024543379A (ja) サイロシビンによる治療抵抗性うつ病の治療
JP2025500844A (ja) 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
HK40068334A (en) Treatment of depression and other various disorders with psilocybin
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251016